News for Vaxart, Inc. (VXRT.MX)

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Vaxart, Inc. previously traded on NASDAQ.

Vaxart (VXRT) stockholders approved the election of six directors and the ratification of the independent auditor. Proposals for reverse stock split and exe

**media[654546]**

**media[651635]**

Vaxart (VXRT) will disclose Phase I norovirus trial results on June 11, 2025. A conference call will be hosted at 8:30 AM ET to review and discuss these

Vaxart (VXRT) has adjourned its 2025 annual stockholders meeting to June 13, 2025. The focus of the adjournment is to secure votes for the reverse stock

**media[643771]**

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT), a clinical-stage biotechnology company developing a range of oral recombin

Vaxart (VXRT) to participate in the Jefferies Global Healthcare Conference on June 5, 2025. Management will engage in a fireside chat at 2:00 PM ET, acc

**media[640877]**

Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms ...

**media[612722]**

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that members of the management team will present at the C

Vaxart (VXRT) has successfully finished enrolling participants for its Phase 1 clinical trial, which is assessing the effectiveness of its new oral norovirus va

- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that it complete

**media[610215]**

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Office

**media[578270]**

Operator: Greetings and welcome to the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference call.